Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entinostat - Syndax Pharmaceuticals

Drug Profile

Entinostat - Syndax Pharmaceuticals

Alternative Names: EDP-103; Entinostat; KHK-2375; MS-27-275; MS-275; SND 275; SNDX-275

Latest Information Update: 30 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nihon Schering; Pfizer; University of Tokyo
  • Developer Bristol-Myers Squibb; Columbia University; Eddingpharm; Genentech; Hoosier Cancer Research Network; Indiana University; Kyowa Kirin; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Pfizer; Syndax Pharmaceuticals; UNC Lineberger Comprehensive Cancer Center
  • Class Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Uveal melanoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Aug 2019 Phase-II clinical trials in Bladder cancer (Combination therapy, Neoadjuvant therapy) in USA (PO) (NCT03978624)
  • 07 Jun 2019 UNC Lineberger Comprehensive Cancer Center plans a phase II trial for Bladder cancer (Combination therapy, In adults, In elderly) in June 2019 (NCT03978624)
  • 24 Apr 2019 National Cancer Institute plans a phase I trial for Solid tumours and Lymphomas (Combination therapy, Late-stage disease, Second line therapy or greater) in May 2019 (PO) (NCT03925428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top